Nanox Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 336.61%
- Profit Growth 28.61%
- Ebitda 87.73%
- Net Worth -86.46%
- Total Assets 5.60%
About Nanox Pharmaceuticals
Nanox Pharmaceuticals Private Limited (NPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 20 July 2021 (Three years and six months 27 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vinay Gupta, Sujata Sinha, and Ritu Gupta serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24290UP2021PTC149094
-
Company No.
149094
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Jul 2021
-
Date of AGM
31 Aug 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Nanox Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Gupta
|
Director | 20-Jul-2021 | Current |
|
Sujata Sinha
|
Director | 20-Jul-2021 | Current |
|
Ritu Gupta
|
Director | 20-Jul-2021 | Current |
Financial Performance of Nanox Pharmaceuticals.
Nanox Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 336.61% increase. The company also saw a substantial improvement in profitability, with a 28.61% increase in profit. The company's net worth observed a substantial decline by a decrease of 86.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nanox Pharmaceuticals?
Unlock access to Nanox Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nanox Pharmaceuticals?
Nanox Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nanox Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nanox Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.